Brief: Protara Gets FDA Clearance To Start Mid-stage Trial Of Tara-002 In Pediatric Patients With Lymphatic Malformations

Protara Therapeutics

02/05/2023 13:51

May 2 (Reuters) - Protara Therapeutics Inc  TARA.O :
    * PROTARA THERAPEUTICS RECEIVES REGULATORY CLEARANCE FROM
FDA TO
COMMENCE PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC
PATIENTS WITH LYMPHATIC MALFORMATIONS
    * PROTARA THERAPEUTICS RECEIVES REGULATORY CLEARANCE FROM
FDA TO
COMMENCE PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC
PATIENTS WITH LYMPHATIC MALFORMATIONS
    * PROTARA THERAPEUTICS RECEIVES REGULATORY CLEARANCE FROM
FDA TO
COMMENCE PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC
PATIENTS WITH LYMPHATIC MALFORMATIONS
    * PROTARA THERAPEUTICS INC - STUDY STARTUP ACTIVITIES
ONGOING;
TRIAL INITIATION EXPECTED IN Q423

Source text for Eikon:  ID:nGNXbG8ff8 
Further company coverage:  TARA.O 

 ((Reuters.Briefs@thomsonreuters.com;))